DrugPatentWatch Database Preview
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE Drug Profile
» See Plans and Pricing
When do Atovaquone And Proguanil Hydrochloride patents expire, and what generic alternatives are available?
Atovaquone And Proguanil Hydrochloride is a drug marketed by Glenmark Generics and Mylan and is included in two NDAs.
The generic ingredient in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.
Summary for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Suppliers / Packagers: | 7 |
Bulk Api Vendors: | 1 |
Clinical Trials: | 22 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE at DailyMed |

Recent Clinical Trials for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Richmond Pharmacology Limited | Phase 1 |
National Center for Parasitology, Entomology and Malaria Control | Phase 4 |
The PATH Malaria Vaccine Initiative (MVI) | N/A |
See all ATOVAQUONE AND PROGUANIL HYDROCHLORIDE clinical trials
Pharmacology for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Drug Class | Antimalarial Antiprotozoal |
Mechanism of Action | Dihydrofolate Reductase Inhibitors |